Comparing Outcomes between Antibody Induction Therapies in Kidney Transplantation
| Autor: | Roy D. Bloom, Jeffrey H. Silber, Wei Wang, Joseph G. Reiter, Bijan A. Niknam, Orit Even-Shoshan, Jesse D. Schold, Susanna M. Nazarian, Alexander S. Hill, Neel Koyawala, Jennifer Trofe-Clark, Mary Ann Lim, Deirdre Sawinski, Paul R. Rosenbaum, Peter P. Reese |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Male
medicine.medical_specialty Basiliximab medicine.medical_treatment Recombinant Fusion Proteins 030232 urology & nephrology 030230 surgery Lower risk Antibodies Monoclonal Humanized Antibodies Cohort Studies 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Animals Humans Clinical Epidemiology Alemtuzumab Kidney transplantation Aged Antilymphocyte Serum Retrospective Studies Aged 80 and over business.industry Proportional hazards model Hazard ratio Antibodies Monoclonal Immunosuppression General Medicine Middle Aged medicine.disease Kidney Transplantation Transplantation Treatment Outcome Nephrology Female Rabbits business Immunosuppressive Agents medicine.drug |
| Popis: | Kidney transplant recipients often receive antibody induction. Previous studies of induction therapy were often limited by short follow-up and/or absence of information about complications. After linking Organ Procurement and Transplantation Network data with Medicare claims, we compared outcomes between three induction therapies for kidney recipients. Using novel matching techniques developed on the basis of 15 clinical and demographic characteristics, we generated 1:1 pairs of alemtuzumab-rabbit antithymocyte globulin (rATG) (5330 pairs) and basiliximab-rATG (9378 pairs) recipients. We used paired Cox regression to analyze the primary outcomes of death and death or allograft failure. Secondary outcomes included death or sepsis, death or lymphoma, death or melanoma, and healthcare resource utilization within 1 year. Compared with rATG recipients, alemtuzumab recipients had higher risk of death (hazard ratio [HR], 1.14; 95% confidence interval [95% CI], 1.03 to 1.26; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|